Design of Phase III, Randomized, Placebo-Controlled Trials of BI 1015550 in Patients with Progressive Fibrosing Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis (FIBRONEER-ILD / -IPF)

Background/Purpose There is a need for better treatments that modify the disease course and improve symptoms of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILD). BI 1015550, a preferential phosphodiesterase 4B inhibitor, prevented lung function decline in a Phase II study in IPF. Based on its anti-inflammatory and antifibrotic properties it may provide an additional treatment option, alone or with nintedanib, in patients with IPF or PF-ILD.